Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $48.71 Average PT from Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has earned a consensus rating of “Moderate Buy” from the eighteen analysts that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $48.71.

NTLA has been the subject of several research analyst reports. Wells Fargo & Company reduced their target price on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “overweight” rating for the company in a report on Friday, January 10th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. BMO Capital Markets reduced their price objective on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday, January 10th. William Blair restated a “neutral” rating and set a $14.00 price objective on shares of Intellia Therapeutics in a report on Monday, November 18th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $90.00 target price on shares of Intellia Therapeutics in a report on Tuesday, November 19th.

Insiders Place Their Bets

In related news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 29,000 shares of company stock valued at $352,551 over the last three months. 3.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Several hedge funds have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Intellia Therapeutics in the 4th quarter worth $25,000. Sterling Capital Management LLC boosted its stake in shares of Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after buying an additional 2,867 shares during the period. Whipplewood Advisors LLC acquired a new stake in shares of Intellia Therapeutics during the 4th quarter worth about $40,000. Eastern Bank acquired a new position in Intellia Therapeutics during the third quarter worth approximately $41,000. Finally, Resona Asset Management Co. Ltd. acquired a new position in Intellia Therapeutics during the fourth quarter worth approximately $43,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NTLA opened at $10.80 on Monday. The firm has a 50-day moving average of $10.94 and a 200-day moving average of $15.79. Intellia Therapeutics has a one year low of $8.96 and a one year high of $34.87. The company has a market cap of $1.10 billion, a PE ratio of -1.99 and a beta of 1.80.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.